Search
for

    GlossaryPP405

    novel molecule for treating hair loss by targeting MPC

    PP405 is a novel small molecule developed by Pelage Pharmaceuticals for the treatment of hair loss, specifically targeting mitochondrial pyruvate carrier (MPC).

    Learn

    1 / 1 results

      learn PP405

      mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    Research

    5 / 31 results

    Community Join

    5 / 413 results

      community Pelage are starting phase 3 for PP405 towards the end of 2026

      in Chat  123 upvotes 21 hours ago
      PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

      community PP405 Hairloss Reversal and Hairline Restoration

      in Treatment  5 upvotes 4 days ago
      PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

      community Will Pp405 be the Ozempic of bald Guys

      in Research/Science  99 upvotes 6 days ago
      PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

      community Who else is looking forward to full phase 2 results of PP405?

      in Chat  59 upvotes 1 week ago
      PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.